Concord Health Partners Research
Investment Thesis
Concord Health Partners is a healthcare-focused growth equity firm headquartered in Summit, New Jersey, founded by James T. Olsen (former Managing Director and Group Head of Healthcare Investment Banking at Jefferies) alongside Joseph Swedish (former Chairman, President & CEO of Anthem, now Elevance Health). The firm's homepage states its mission directly: "We invest in companies with innovative technologies and solutions that advance healthcare through operational efficiencies, improved patient outcomes and expanded access to care." Concord's stated approach page emphasizes that healthcare is a highly complex industry shaped by clinical, policy, reimbursement, and technology considerations, and that the firm's collective domain knowledge, proprietary relationships, and broad network of healthcare executives let it identify compelling opportunities and create incremental value for portfolio companies and co-investors alike.
Sector Focus
Concord invests exclusively in healthcare, spanning Healthcare Services, Medical Technology, Healthcare IT, and Tech-Enabled Services (per the firm's own site copy). Portfolio sub-themes include value-based / risk-bearing oncology care (Thyme Care), AI-driven revenue cycle management and clinical documentation automation (Smarter Technologies, combining SmarterDx, Access Healthcare, and Pieces Technologies), network intelligence and patient activation (Clarify Health, which acquired Loyal Health in 2026), spine and minimally invasive surgical technology (Highridge Medical, which acquired select Accelus product lines in September 2025), digital/virtual psychiatry and behavioral health (Iris Telehealth, NeuroFlow, Learn to Live), critical care telehealth (Hicuity Health), post-acute care analytics (Post Acute Analytics), AI clinical decision support (Mednition), patient financial experience (Cedar), neurorehabilitation technology (MindMaze Therapeutics), and diagnostic imaging networks (Scan.com).
Stage Focus
Concord targets innovative growth-stage and expansion-stage healthcare companies. It has led earlier-stage rounds for less mature portfolio companies (e.g., leading Mednition's $10M Series A in 2019) while also participating as one of several institutional/strategic investors in larger, later-stage growth rounds (e.g., Thyme Care's $125M+ Series E in 2026, valuing the company above $2B; Scan.com's $90M Series C in August 2026 led by Noteus Partners).
Check Size
No explicit check-size range is published. Disclosed deal sizes Concord has participated in or led range from roughly $10M (Mednition Series A, led) to $105M (MindMaze Therapeutics financing, led, 2022) up to participation in $90M-$125M+ rounds alongside strategics and other institutional investors, indicating flexibility depending on lead-vs-follow role.
Lead Tendency
Mixed ("both"). Concord has led rounds for earlier-stage or single-sponsor deals (Mednition Series A; MindMaze Therapeutics $105M financing, 2022; Accelus Series D, 2022) while regularly participating alongside strategics and other institutional investors in larger syndicated growth rounds (Thyme Care Series E alongside Morgan Health, Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health; Scan.com Series C alongside Noteus Partners (lead), Aviva, YZR Capital, and Oxford Capital).
Recent Activity
Concord has raised at least three vehicles: a $50M early-stage fund launched with the American Hospital Association (2019), Concord Innovation Fund II at $150M (final close September 2022), and Concord Innovation Fund III, targeting $250M per a 2024 regulatory filing; combined reported AUM is approximately $316M per third-party trackers. 2026 has been an active year across the portfolio: Clarify Health named co-founder Todd Gottula CEO in May 2026; Thyme Care was named to the CNBC Disruptor 50 list in May 2026; Clarify Health acquired Loyal Health around mid-2026 to build a closed-loop network intelligence and patient activation platform; Concord participated in Scan.com's $90M Series C (part of a $220M combined equity-and-debt financing) in August 2026 to build the largest medical imaging network in the US; and Concord participated in Thyme Care's $125M+ Series E in September 2026, which also established "Thyme Companies" to broaden its impact across the oncology ecosystem.
Portfolio Highlights
Current and recent portfolio companies (per the firm's own portfolio page and news coverage) include Thyme Care (oncology care, >$2B valuation), Smarter Technologies (RCM/clinical documentation automation, combining SmarterDx, Access Healthcare, and Pieces Technologies), Highridge Medical (spine and MIS surgical technology), Iris Telehealth (psychiatry), NeuroFlow (behavioral health analytics), Cedar (patient financial experience), Hicuity Health (critical care telehealth, formerly Advanced ICU Care), Post Acute Analytics (post-acute care AI), Mednition (AI clinical decision support), Clarify Health (network intelligence, now including Loyal Health), Learn to Live (digital mental health), MindMaze Therapeutics (neurorehabilitation technology, $105M financing led by Concord in 2022), and Scan.com (medical imaging network). Accelus (spinal implant technology) was a prior portfolio company whose select product lines were acquired by Highridge Medical in September 2025.
Team
- James T. Olsen, Founder & Managing Partner: former Managing Director and Group Head, Healthcare Investment Banking at Jefferies; 20+ years in healthcare investment banking.
- Benson Jose, Partner / COO / CFO.
- Joseph Swedish, Partner Emeritus (Co-Founder): former Chairman, President & CEO of Anthem (now Elevance Health).
- George Hoffmann, Principal.
- Edward Abraham, Principal.
- Robert B. Schulz, Managing Director: healthcare private equity veteran.
- Brian Gragnolati, Executive Partner: healthcare system executive.
Decision Process
Not explicitly disclosed. Concord is a small, partner-led shop (Olsen, Jose, Swedish, and a small group of Principals/Managing Directors/Executive Partners), consistent with a partnership-style decision process rather than a large formal investment committee.
Founder Preferences
Concord favors management teams building technology-enabled or tech-adjacent healthcare businesses that address cost, quality, or access problems in complex, regulated corners of the healthcare system, and that can benefit from Concord's operating network of health-system and payer relationships and board-level involvement.
Geographic Focus
Concord is headquartered in Summit, New Jersey, and invests primarily in U.S. healthcare companies; the portfolio is nationally distributed (imaging network in Scan.com even spans US and UK) rather than regionally concentrated.